<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37465879</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Neuromuscular junction denervation and terminal Schwann cell loss in the hTDP-43 overexpression mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e12925</StartPage><MedlinePgn>e12925</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12925</ELocationID><Abstract><AbstractText Label="AIMS">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with complex aetiology. Despite evidence of neuromuscular junction (NMJ) denervation and 'dying-back' pathology in models of SOD1-dependent ALS, evidence in other genetic forms of ALS is limited by a lack of suitable animal models. TDP-43, a key mediator protein in ALS, is overexpressed in neurons in Thy1-hTDP-43<sup>WT</sup> mice. We therefore aimed to comprehensively analyse NMJ pathology in this model of ALS.</AbstractText><AbstractText Label="METHODS">Expression of TDP-43 was assessed via western blotting. Immunohistochemistry techniques, alongside NMJ-morph quantification, were used to analyse motor neuron number, NMJ denervation status and terminal Schwann cell morphology.</AbstractText><AbstractText Label="RESULTS">We present a time course of progressive, region-specific motor neuron pathology in Thy1-hTDP-43<sup>WT</sup> mice. Thy1-driven hTDP-43 expression increased steadily, correlating with developing hindlimb motor weakness and associated motor neuron loss in the spinal cord with a median survival of 21&#x2009;days. Pronounced NMJ denervation was observed in hindlimb muscles, mild denervation in cranial muscles but no evidence of denervation in either forelimb or trunk muscles. NMJ pathology was restricted to motor nerve terminals, with denervation following the same time course as motor neuron loss. Terminal Schwann cells were lost from NMJs in hindlimb muscles, directly correlating with denervation status.</AbstractText><AbstractText Label="CONCLUSIONS">Thy1-hTDP-43<sup>WT</sup> mice represent a severe model of ALS, with NMJ pathology/denervation of distal muscles and motor neuron loss, as observed in ALS patients. This model therefore provides an ideal platform to investigate mechanisms of dying-back pathology, as well as NMJ-targeting disease-modifying therapies in ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alhindi</LastName><ForeName>Abrar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Anatomy, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shand</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Hannah L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Ana S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, UNESP-S&#xe3;o Paulo State University, Botucatu, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Hoorn</LastName><ForeName>Dinja</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridgway</LastName><ForeName>Zara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faller</LastName><ForeName>Kiterie M E</ForeName><Initials>KME</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Ross A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillingwater</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaytow</LastName><ForeName>Helena</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2257-7620</Identifier><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C088568">aspartyl-arginyl-valyl-tyrosyl-isoleucyl-histidyl-prolyl-phenylalanyl-histidyl-leucyl-valyl-isoleucyl-histidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012583" MajorTopicYN="N">Schwann Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NMJ denervation</Keyword><Keyword MajorTopicYN="N">TDP-43 proteinopathies</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">transgenic mouse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37465879</ArticleId><ArticleId IdType="doi">10.1111/nan.12925</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/S0140-6736(17)31287-4</Citation></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540-549. doi:10.1136/jnnp-2016-315018</Citation></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30(11):3655-3662.e2. doi:10.1016/j.celrep.2020.02.078</Citation></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S a. 2013;110(8):E736-E745. doi:10.1073/pnas.1222809110</Citation></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong L, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (80-). 2006;314(5796):130-133. doi:10.1126/science.1134108</Citation></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470-477. doi:10.1007/s12031-010-9467-1</Citation></Reference><Reference><Citation>Santosa KB, Keane AM, Jablonka-Shariff A, Vannucci B, Snyder-Warwick AK. Clinical relevance of terminal Schwann cells: an overlooked component of the neuromuscular junction. J Neurosci Res. 2018;96(7):1125-1135. doi:10.1002/jnr.24231</Citation></Reference><Reference><Citation>Bjornskov EK, Norris FH, Mower-Kuby J. Quantitative axon terminal and end-plate morphology in amyotrophic lateral sclerosis. Arch Neurol. 1984;41(5):527-530. doi:10.1001/archneur.1984.04050170073021</Citation></Reference><Reference><Citation>Tsujihata M, Hazama R, Yoshimura T, Satoh A, Mori M, Nagataki S. The motor end-plate fine structure and ultrastructural localization of acetylcholine receptors in amyotrophic lateral sclerosis. Muscle Nerve. 1984;7(3):243-249. doi:10.1002/mus.880070310</Citation></Reference><Reference><Citation>Yu H, Chen L, Zhang S, He J, Fan D. Early axonal dysfunction of the peripheral nervous system influences disease progression of ALS: evidence from clinical neuroelectrophysiology. Front Neurol. 2021;12(February):1, 574919-8. doi:10.3389/fneur.2021.574919</Citation></Reference><Reference><Citation>Jenkins TM, Alix JJP, Fingret J, et al. Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease. J Neurol. 2019;267(1):0123456789. doi:10.1007/s00415-019-09580-x</Citation></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2016;69. doi:10.1002/0471141755.ph0567s69.Rodent</Citation></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3(4):431-457. doi:10.1002/brb3.142</Citation></Reference><Reference><Citation>Narai H, Manabe Y, Nagai M, et al. Early detachment of neuromuscular junction proteins in ALS mice with SODG93A mutation. Neurol Int. 2009;1(1):16, e16. doi:10.4081/ni.2009.e16</Citation></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33(1):409-440. doi:10.1146/annurev.neuro.051508.135722</Citation></Reference><Reference><Citation>Tosolini AP, Sleigh JN, Surana S, Rhymes ER, Cahalan SD, Schiavo G. BDNF-dependent modulation of axonal transport is selectively impaired in ALS. Acta Neuropathol Commun. 2022;10(1):121. doi:10.1186/s40478-022-01418-4</Citation></Reference><Reference><Citation>Alhindi A, Boehm I, Chaytow H. Small junction, big problems: neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS). J Anat. 2022;241(5):1089-1107. doi:10.1111/joa.13463</Citation></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602-611. doi:10.1016/j.bbrc.2006.10.093</Citation></Reference><Reference><Citation>Pamphlett R, Luquin N, McLean C, Jew SK, Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. Neuropathol Appl Neurobiol. 2009;35(2):222-225. doi:10.1111/j.1365-2990.2008.00982.x</Citation></Reference><Reference><Citation>Gordon D, Dafinca R, Scaber J, et al. Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol Dis. 2019;121(September 2018):148-162. doi:10.1016/j.nbd.2018.09.024</Citation></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knockin mouse model of ALS. Cell Rep. 2019;26(2):364-373.e4. doi:10.1016/j.celrep.2018.12.045</Citation></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12(1):6914. doi:10.1038/s41467-021-27221-8</Citation></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci. 2010;107(8):3858-3863. doi:10.1073/pnas.0912417107</Citation></Reference><Reference><Citation>Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):863-885. doi:10.1007/s00401-017-1708-8</Citation></Reference><Reference><Citation>Chaytow H, Carroll E, Gordon D, et al. Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis. EBioMedicine. 2022;83:104202. doi:10.1016/j.ebiom.2022.104202</Citation></Reference><Reference><Citation>Alhindi A, Boehm I, Forsythe RO, et al. Terminal Schwann cells at the human neuromuscular junction. Brain Commun. 2021;44(2):fcab081. doi:10.1093/braincomms/fcab081</Citation></Reference><Reference><Citation>Minty G, Hoppen A, Boehm I, et al. ANMJ-morph: a simple macro for rapid analysis of neuromuscular junction morphology. R Soc Open Sci. 2020;7(4):200128. doi:10.1098/rsos.200128</Citation></Reference><Reference><Citation>Jones RA, Reich CD, Dissanayake KN, et al. NMJ-morph reveals principal components of synaptic morphology influencing structure-function relationships at the neuromuscular junction. Open Biol. 2016;6(12):160240. doi:10.1098/rsob.160240</Citation></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, et al. Neurotechnique imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP variants with altered spectral properties and improved translational efficiency, thermostability, and quantum yield. As a result of these favorable pro. Neuron. 2000;28(1):41-51. doi:10.1016/S0896-6273(00)00084-2</Citation></Reference><Reference><Citation>Riessland M, Ackermann B, F&#xf6;rster AF, et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010;19(8):1492-1506. doi:10.1093/hmg/ddq023</Citation></Reference><Reference><Citation>Spiller KJ, Cheung CJ, Restrepo CR, et al. Selective motor neuron resistance and recovery in a new inducible mouse model of TDP-43 proteinopathy. J Neurosci. 2016;36(29):7707-7717. doi:10.1523/JNEUROSCI.1457-16.2016</Citation></Reference><Reference><Citation>Liu JX, Br&#xe4;nnstr&#xf6;m T, Andersen PM, Pedrosa-Domell&#xf6;f F. Distinct changes in synaptic protein composition at neuromuscular junctions of extraocular muscles versus limb muscles of ALS donors. PLoS ONE. 2013;8(2):e57473. doi:10.1371/journal.pone.0057473</Citation></Reference><Reference><Citation>Bruneteau G, Bauch&#xe9; S, Gonzalez de Aguilar JL, et al. Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2015;2(4):362-372. doi:10.1002/acn3.179</Citation></Reference><Reference><Citation>Gould TW, Buss RR, Vinsant S, et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci. 2006;26(34):8774-8786. doi:10.1523/JNEUROSCI.2315-06.2006</Citation></Reference><Reference><Citation>Jones RA, Harrison C, Eaton SL, et al. Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep. 2017;21(9):2348-2356. doi:10.1016/j.celrep.2017.11.008</Citation></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12(February):1-36. doi:10.3389/fnmol.2019.00025</Citation></Reference><Reference><Citation>Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat. 2013;34(6):812-826. doi:10.1002/humu.22319</Citation></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (80-). 2008;319(5870):1668-1672. doi:10.1126/science.1154584</Citation></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409-416. doi:10.1016/S1474-4422(08)70071-1</Citation></Reference><Reference><Citation>Huang C, Xia PY, Zhou H. Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime. Int J Biol Sci. 2010;6(4):396-406. doi:10.7150/ijbs.6.396</Citation></Reference><Reference><Citation>Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2010;285(9):6826-6834. doi:10.1074/jbc.M109.061846</Citation></Reference><Reference><Citation>Er&#xe9;ndira Avenda&#xf1;o-V&#xe1;zquez S, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012;26(15):1679-1684. doi:10.1101/gad.194829.112</Citation></Reference><Reference><Citation>Young AL, Vogel JW, Robinson JL, et al. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies. Brain Published online May 8. 2023;146(7):2975-2988. doi:10.1093/brain/awad145</Citation></Reference><Reference><Citation>Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138:54-70. doi:10.1111/jnc.13588</Citation></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416-438. doi:10.1016/j.neuron.2013.07.033</Citation></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232-240. doi:10.1016/j.expneurol.2003.10.004</Citation></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918-1929. doi:10.1111/ene.14393</Citation></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006;9(3):408-419. doi:10.1038/nn1653</Citation></Reference><Reference><Citation>Bolliger MF, Zurlinden A, L&#xfc;scher D, et al. Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction. J Cell Sci. 2010;123(22):3944-3955. doi:10.1242/jcs.072090</Citation></Reference><Reference><Citation>Mech AM, Brown AL, Schiavo G, Sleigh JN. Morphological variability is greater at developing than mature mouse neuromuscular junctions. J Anat. 2020;237(4):603-617. doi:10.1111/joa.13228</Citation></Reference><Reference><Citation>Boehm I, Miller J, Wishart TM, et al. Neuromuscular junctions are stable in patients with cancer cachexia. J Clin Invest. 2020;130(3):1461-1465. doi:10.1172/JCI128411</Citation></Reference><Reference><Citation>Martin LJ, Wong M. Skeletal muscle-restricted expression of human SOD1 in transgenic mice causes a fatal ALS-like syndrome. Front Neurol. 2020;11(December):1, 592851-26. doi:10.3389/fneur.2020.592851</Citation></Reference><Reference><Citation>Kang H, Tian L, Mikesh M, Lichtman JW, Thompson WJ. Terminal Schwann cells participate in neuromuscular synapse remodeling during reinnervation following nerve injury. J Neurosci. 2014;34(18):6323-6333. doi:10.1523/JNEUROSCI.4673-13.2014</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>